Published Date: 12 Aug 2024
Early recurrence after anti-PD-1/L1 likely to benefit more from anti-CTLA-4, targeted agents
Read Full News© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation